The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Chronic hepatitis B (CHB) seriously threatens human health. About 820,000 deaths annually are due to related complications such as hepatitis B and hepatocellular carcinoma (HCC). Recently, the use of oral antiviral agents has significantly improved the prognosis of patients with CHB infection and reduced the risk of HCC. However, hepatitis B virus still remains a major factor in the development of HCC, raising many concerns. Therefore, numerous studies have been conducted to assess the risk of HCC in patients with CHB infection and many models have been proposed to predict the risk of developing HCC. However, as each study has different models for predicting HCC development that can be applied depending on the use of antiviral agents or the type of antiviral agents, it is necessary to properly understand characteristics of each model when using it for the evaluation of HCC in patients with CHB infection. In addition, because different variables such as host factor, viral activity, and cirrhosis are used to evaluate the risk of HCC development, it is necessary to assess the risk by carefully verifying which variables are used. Recently, studies have also evaluated the risk of HCC using risk prediction models through transient elastography and artificial intelligence (AI) system. These HCC risk predication models are also noteworthy. In this review, we aimed to compare HCC risk prediction models in patients with CHB infection reported to date to confirm variables used and specificity between each model to determine an appropriate HCC risk prediction method.
Abstract
Chronic hepatitis B (CHB) seriously threatens human health. About 820,000 deaths annually are due to related complications such as hepatitis B and hepatocellular carcinoma (HCC). Recently, the use of oral antiviral agents has significantly improved the prognosis of patients with CHB infection and reduced the risk of HCC. However, hepatitis B virus still remains a major factor in the development of HCC, raising many concerns. Therefore, numerous studies have been conducted to assess the risk of HCC in patients with CHB infection and many models have been proposed to predict the risk of developing HCC. However, as each study has different models for predicting HCC development that can be applied depending on the use of antiviral agents or the type of antiviral agents, it is necessary to properly understand characteristics of each model when using it for the evaluation of HCC in patients with CHB infection. In addition, because different variables such as host factor, viral activity, and cirrhosis are used to evaluate the risk of HCC development, it is necessary to assess the risk by carefully verifying which variables are used. Recently, studies have also evaluated the risk of HCC using risk prediction models through transient elastography and artificial intelligence (AI) system. These HCC risk predication models are also noteworthy. In this review, we aimed to compare HCC risk prediction models in patients with CHB infection reported to date to confirm variables used and specificity between each model to determine an appropriate HCC risk prediction method.
참고문헌 (38)
- Forner A, "Hepatocellular carcinoma", Lancet, 391, pp.1301~1314 (2018)
- Kulik L, "Epidemiology and management of hepatocellular carcinoma", Gastroenterology, 156, pp.477~491 (2019)
- Ioannou GN, "Chronic hepatitis B infection : a global disease requiring global strategies", Hepatology, 58, pp.839~843 (2013)
- Schmit N, "The global burden of chronic hepatitis B virus infection : comparison of countrylevel prevalence estimates from four research groups", Int J Epidemiol, 50, pp.560~569 (2021)
- Liaw YF, "Lamivudine for patients with chronic hepatitis B and advanced liver disease", N Engl J Med, 351, pp.1521~1531 (2004)
- European Association for the Study of the Liver, "EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
- Korean Association for the Study of the Liver (KASL), "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 25(2), pp.93~159 (2019), 대한간학회
- Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
- Seung Bum Lee, "Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir", Clinical and Molecular Hepatology, 26(3), pp.364~375 (2020), 대한간학회[DOI]
- Lau G, "APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy", Hepatol Int, 15, pp.1031~1048 (2021)
- Chang TT, "Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B", Hepatology, 51, pp.422~430 (2010)
- Marcellin P, "Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B : a 5-year open-label follow-up study", Lancet, 381, pp.468~475 (2013)
- Sung Won Lee, "Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma", Clinical and Molecular Hepatology, 27(3), pp.402~412 (2021), 대한간학회[DOI]
- Yu JH, "Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir", tenofovir, 2019, pp.31, 865~872
- Cong M, "A predictive model using N-glycan biosignatures for clinical diagnosis of early hepatocellular carcinoma related to hepatitis B virus", OMICS, 24, pp.415~423 (2020)
- Van Hees S, "Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma", World J Gastroenterol, 22, pp.8271~8282 (2016)
- Yuen MF, "Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B", J Hepatol, 50, pp.80~88 (2009)
- Wong VW, "Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers", J Clin Oncol, 28, pp.1660~1665 (2010)
- Yang HI, "Risk estimation for hepatocellular carcinoma in chronic hepatitis B(REACH-B) : development and validation of a predictive score", Lancet Oncol, 12, pp.568~574 (2011)
- Lee MH, "Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients : risk scores integrating host and virus profiles", Hepatology, 58, pp.546~554 (2013)
- Kim DY, "Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma : development and validation of a predictive model", Onco Targets Ther, 6, pp.1463~1469 (2013)
- Wong GL, "Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B", J Hepatol, 60, pp.339~345 (2014)
- Shin SH, "Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection : comparison with histological fibrosis", Liver Int, 35, pp.1054~1062 (2015)
- Poh Z, "Realworld risk score for hepatocellular carcinoma(RWS-HCC) : a clinically practical risk predictor for HCC in chronic hepatitis B", Gut, 65, pp.887~888 (2016)
- Fan C, "A simple AGED score for risk classification of primary liver cancer : development and validation with long-term prospective HBsAg-positive cohorts in Qidong, China", Gut, 68, pp.948~949 (2019)
- 신동현, "A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels", Gut and Liver, 11(4), pp.528~534 (2017), 거트앤리버 소화기연관학회협의회
- Papatheodoridis G, "PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy", J Hepatol, 64, pp.800~806 (2016)
- Kim JH, "Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy", J Hepatol, 69, pp.1066~1073 (2018)
- Hsu YC, "Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B", J Hepatol, 69, pp.278~285 (2018)
- 손원, "Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B", Clinical and Molecular Hepatology, 23(2), pp.170~178 (2017), 대한간학회[DOI]
- Chen CH, "Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir", Oncotarget, 8, pp.92431~92441 (2017)
- Chon HY, "Addition of liver stiffness enhances the predictive accuracy of the PAGE-B model for hepatitis B-related hepatocellular carcinoma", Aliment Pharmacol Ther, 53, pp.919~927 (2021)
- Lee HW, "Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy", Am J Gastroenterol, 109, pp.1241~1249 (2014)
- Seo YS, "Validation of risk prediction models for the development of HBVrelated HCC : a retrospective multi-center 10-year follow-up cohort study", Oncotarget, 8, pp.113213~113224 (2017)
- Wu S, "Hepatocellular carcinoma prediction models in chronic hepatitis B : a systematic review of 14 models and external validation", Clin Gastroenterol Hepatol, 19, pp.2499~2513 (2021)
- Yang HI, "Real-world effectiveness from the Asia Pacific Rim Liver Consortium for HBV risk score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients treated with oral antiviral therapy", J Infect Dis, 221, pp.389~399 (2020)
- Chang JW, "Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir", J Viral Hepat, 28, pp.95~104 (2021)
- Kim HY, "An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B", J Hepatol, 76, pp.311~318 (2022)